✦ LIBER ✦

Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia

✍ Scribed by Djamel Ben Smail; Claire Jacq; Pierre Denys; Bernard Bussel

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 79 KB
Volume: 20
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20405

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We report on the case of a patient suffering from Friedreich's ataxia (FA) with very painful and disabling spasms that were improved markedly by intrathecal baclofen infusion. To our knowledge, this is the first report of an intrathecal baclofen‐delivering pump implantation in an FA patient. © 2005 Movement Disorder Society

📜 SIMILAR VOLUMES

Intrathecal baclofen in the treatment of

Intrathecal baclofen in the treatment of dystonic storm

✍ Arif Dalvi; Stanley Fahn; Blair Ford 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB

Paraneoplastic cerebellar degeneration is a complication of malignancies characterized by truncal and appendicular ataxia, dysarthria, and nystagmus. The pathologic hallmark of the dis-A videotape accompanies this article.

Analysis of the factors influencing the

Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia

✍ Bheeshma Rajagopalan; Jane M. Francis; Fraser Cooke; L. V. Prasad Korlipara; And 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Friedreich's ataxia (FRDA) has been associated with both cardiac hypertrophy and to a lesser degree dilated cardiomyopathy. We have conducted a cross sectional magnetic resonance imaging (MRI) study of 25 patients with clinically and genetically confirmed FRDA and 24 healthy controls to analyse how

Could thiazolidinediones increase the ri

Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?

✍ José L. García-Giménez; Fabián Sanchis-Gomar; Federico V. Pallardó 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Clinical evidence and the recent decisions of the European Medicines Agency and the Food and Drug Administration challenge the safety of thiazolidinediones treatment. Recently, this treatment has been suggested for Friedreich's ataxia because thiazolidinediones improve neurological symptoms. Hypertr

Abnormal activity of membrane phospholip

Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich's ataxia and spinocerebellar atrophy type-1

✍ Brian M. Ross; Klaus Eder; Anna Moszczynska; Nikolaos Mamalias; Jacques Lamarche 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

Much evidence, derived from biochemical studies of both blood and autopsied brain, has suggested that phospholipid metabolism is abnormal in patients with Friedreich's ataxia (FA), a disorder characterized by severe neuronal loss in the spinal cord and lower brain stem with no, or only modest, damag

The impact of treatment of depression on

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Margery H. Mark; Michae 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to one million individuals in the United States. Depression is found in 40 to 50% of these patients and is associated with a variety of poor outcomes for both patients and their families. Despite this, there are

Review of donepezil, rivastigmine, galan

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population

✍ V. P. Prasher 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability